Resolution of 9-(c-4,t-5-bishydroxymethylcyclopent-2-en-r-1-yl)-9H-adenine and selective inhibition of human immunodeficiency virus by the (-) enantiomer.
Two enantiomers of 9-(c-4,t-5-bishydroxymethylcyclopent-2-en-r-1-yl)-9H- adenine (BCA) which showed a potent and selective anti-HIV effects have been synthesized and evaluated against human immunodeficiency virus type 1. The result demonstrated that the potent-HIV activity of racemic BCA is expressed solely by the (-) isomer.
Katagiri
N
N
Pharmaceutical Institute, Tohoku University, Sendai, Japan.
Shiraishi
T
T
Sato
H
H
Toyota
A
A
Kaneko
C
C
Yusa
K
K
Oh-hara
T
T
Tsuruo
T
T
D000225:Adenine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003517:Cyclopentanes / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D013237:Stereoisomerism
D000998:Antiviral Agents; D003517:Cyclopentanes; C074108:9-(4,5-bishydroxymethylcyclopent-2-en-1-yl)-9H-adenine; D000225:Adenine